Hostname: page-component-78c5997874-dh8gc Total loading time: 0 Render date: 2024-11-10T10:04:41.901Z Has data issue: false hasContentIssue false
  • English
  • Français

Drug Treatments of Dementia

Published online by Cambridge University Press:  02 January 2018

L. J. Whalley
L. J. Whalley*
Affiliation:
Edinburgh University Department of Psychiatry, The Kennedy Tower, Royal Edinburgh Hospital, Morningside Park, Edinburgh EH10 5HF
Get access Rights & Permissions [Opens in a new window]

Abstract

Present drug treatments for the more common types of dementia are largely palliative or symptomatic, but the promise of drugs to prevent the development of dementia does not seem unrealistic. Neuropharmacological strategies that aim to improve behavioural or cognitive symptoms in dementia are subdivided into drugs that modify central cholinergic, serotonergic, dopaminergic, GABAnergic, and peptidergic transmission. There are no clear clinical guidelines for the management of demented patients who are also hypertensive. The early identification of patients with incipient dementia, the detection of slight but theoretically important beneficial effects, the optimum method of drug administration, more soundly based treatment of behavioural symptoms, and the evaluation of drug combinations are all identified as areas requiring further research.

Type
Review Article
Information
The British Journal of Psychiatry , Volume 155 , Issue 5 , November 1989 , pp. 595 - 611
Copyright
Copyright © Royal College of Psychiatrists, 1989 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Arendt, T., Allen, Y., Sinden, J., et al (1988) Cholinergic-rich brain transplants reverse alcohol-induced memory deficits. Nature, 332, 448–450.Google Scholar
Arnstein, A. F. T., Segal, D. S., Neville, H. J., et al (1983) Naloxone augments electrophysiological signs of selective attention in man. Nature, 304, 725–727.Google Scholar
Arnstein, A. F. T. & Goldman-Rakic, P. S. (1985) Alpha 2 andrenergic mechanisms in prefrontal cortex associated with cognitive decline in aged nonhuman primates. Science, 230, 1273–1276.Google Scholar
Ather, S. A. Shaw, S. H. & Stoker, M. J. (1986) A comparison of chlormethiazole and thioridazine in agitated confusional states of the elderly. Acta Psychiatrica Scandinavica (suppl.), 329, 81–89.CrossRefGoogle ScholarPubMed
Avery, S. F., Russel, R. W. R. & Crockard, H. A. (1983) Naloxone in experimental-ischemia. Journal of Neurology, Neurosurgery and Psychiatry, 46, 189–193.Google Scholar
Barnes, R., Veitch, R., Okimoto, J., et al (1982) Efficacy of antipsychotic medications in behaviourally disturbed dementia patients. American Journal of Psychiatry, 139, 1170–1175.Google ScholarPubMed
Barton, R. & Hurst, L. (1966) Unnecessary use of tranquilisers in elderly patients. British Journal of Psychiatry, 112, 989–990.Google Scholar
Bartus, R. T. & Dean, R. L. (1982) The cholinergic hypothesis of geriatric memory dysfunction Science, 217, 408–412.Google Scholar
Bartus, R. T., Dean, R. L., Pontecorro, M. J., et al (1985) The cholinergic hypothesis: a historical overview, current perspective, and future directions. Annals New York Academy of Sciences, 444, 332–358.Google Scholar
Bayer, A. J., Bayer, E. M., Pathy, M. S., et al (1986) A double-blind study of chlormethiazide and triazolam as hypnotics in the elderly. Acta Psychiatrica Scandinavica, 329, 104–111.Google Scholar
Bergmann, K., Kay, D. W., Foster, E. M., et al (1971) A follow-up of randomly selected community residents to assess the effects of chronic brain syndrome and cerebrovascular disease. New Prospects in the Study of Mental Disorders in Old Age, pp. 856–865. Proceedings of the Fifth World Congress of Psychiatry, Mexico. Amsterdam: Excerpta Medica.Google Scholar
Betts, T. A., Knight, R., Crowe, A., et al (1985) Effects of beta-blockers on psychomotor performance in normal volunteers. European Journal of Clinical Pharmacology 28 (suppl.), 39–49.Google Scholar
Black, I. A., Adler, J. A., Dreyfus, C. F. et al (1987) Biochemistry of information storage in the nervous system. Science, 236, 1263–1268.Google Scholar
Braham, J. (1971) Jakob–Creutzfeldt disease: treatment by amantadine. British Medical Journal, iv, 212–213.Google Scholar
Britton, K., Granowska, M., Nimmon, C. C., et al (1985) Cerebral blood flow in hypertensive patients with cerebrovascular disease: technique for measurements and effects of captopril. Nuclear Medicine Communications, 6, 251–261.Google Scholar
Bruno, G., Mohr, E., Gillespie, M., et al (1986) Muscarinic agonist therapy of Alzheimer's disease. Archives of Neurology, 43, 659–661.Google Scholar
Caine, E. D. (1980) Cholinomimetic treatment fails to improve memory disorders. New England Journal of Medicine, 303, 585–586.Google Scholar
Callender, J. S., Medley, I. R. & Robertso, J. I. (1986) Psychological effects of nicardipine and proranolol on hypertensive patients. British Journal of Clinical Pharmacology, 22, S267–S272.Google Scholar
Castleden, C. M., George, C. F., Marcer, D., et al (1977) Increased sensitivity to nitrazepam in old age. British Medical Journal, i, 10–12.Google Scholar
Christie, J. E., Shering, P. A., Ferguson, J., et al (1981) Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia. British Journal of Psychiatry, 138, 46–50.Google Scholar
Cohen, E. L. & Wurtman, R. J. (1975) Brain acetylcholine: increase after systemic choline administration. Life Sciences, 16, 1095–1099.Google Scholar
Croog, S. H., Levine, S., Tests, M., et al (1986) The effects of antihypertensive therapy on the quality of life. New England Journal of Medicine, 314, 1657–1664.Google Scholar
Cutler, N. R., Haxby, J., Kay, A. D., et al (1985a) Evaluation of zimelidine in Alzheimer's disease. Archives of Neurology, 42, 744–748.Google Scholar
Cutler, N. R., Haxby, J., Narang, P. K., et al (1985b) Evaluation of an analogue of somatostatin (L363, 586) in Alzheimer's disease. New England Journal of Medicine, 312, 725.Google Scholar
Cutting, J. (1978) The relationship between Korsakov's syndrome and “alcoholic dementia”. British Journal of Psychiatry, 132, 240–251.CrossRefGoogle Scholar
David, A. S., Grant, R. & Ballantyne, J. P. (1984) Unsuccessful treatment of Creutzfeldt–Jakob disease with acyclovir. Lancet, i, 512.Google Scholar
Davies, P. & Maloney, A. J. F. (1976) Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet, ii, 1403.CrossRefGoogle ScholarPubMed
Davis, K. L., Hollister, L. E. & Barchas, J. (1976) Choline in tardive dyskinesia and Huntington's disease. Life Sciences, 19, 1507–1515.Google Scholar
Davis, K. L., Mohs, R. C., Tinklenberg, J. H., et al (1978) Physostigmine, enhancement of long-term memory processes in normal subjects. Science, 201, 272–274.Google Scholar
Davis, K. L., Mohs, R. C. & Tinklenberg, J. H., (1979) Enhancement of memory by physostigmine. New England Journal of Medicine, 301, 946–947.Google Scholar
Davis, K. L. & Mohs, R. C. (1982) Enhancement of memory processes in Alzheimer's disease with multiple dose intravenous physostigmine. American Journal of Psychiatry, 139, 1421–1424.Google Scholar
Davis, K. L. & Mohs, R. C. (1983) Memory enhancement with oral phystostigmine in Alzheimer's disease (letter). New England Journal of Medicine, 308, 721.Google Scholar
Davis, K. L., Hollander, E., Davidson, M., et al (1987) Introduction of depression with oxotremorine in patients with Alzheimer's disease. American Journal of Psychiatry, 144, 468–471.Google Scholar
Dehlin, O., Hedenrud, B., Jansson, P., et al (1985) A double-blind comparison of alaproclate and placebo in the treatment of patients with senile dementia. Acta Psychiatrica Scandinavica, 71, 190–196.Google Scholar
Drachman, D. A. (1977) Memory and cognitive function in man: does the cholinergic system have a specific role? Neurology, 27, 783–790.CrossRefGoogle ScholarPubMed
Drachman, D. A. & Levitt, J. (1974) Human memory and the cholinergic system. Archives of Neurology, 30, 113–121.Google Scholar
Durso, R., Redio, P., Browers, P., et al (1982) Lysine vasopressin in Alzheimer's disease. Neurology, 32, 674–677.Google Scholar
Eliot, F. A. (1977) Propranolol for the control of the belligerent behaviour following acute brain damage. Annals of Neurology, 17, 489–491.Google Scholar
Farmer, M. E., White, L. R., Abbott, R. D., et al (1987) Blood pressure and cognitive performance: the Framingham study. American Journal of Epidemiology, 126, 1103–1114.CrossRefGoogle ScholarPubMed
Fischer, W., Wictorin, K., Bjorkland, A., et al (1987) Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats with nerve growth factor. Nature, 329, 65–68.Google Scholar
Fleischhacker, W. W., Buchgeher, A. & Schubert, H. (1986) Memantine in the treatment of senile dementia of the Alzheimer type. Progress in Neuropsychopharmacology and Biological Psychiatry, 10, 87–93.Google Scholar
Furlow, T. W. & Whitley, R. J. (1982) Repeated suppression of Creutzfeld–Jakob disease with vidarabine. Lancet, ii, 564–565.Google Scholar
Gajdusek, D. S. (1977) Unconventional viruses and the origin and disappearance of Kuru. Science, 197, 943–960.Google Scholar
Gamzu, E. R. (1988) Animal model studies of benzodiazepine-induced amnesia. In Benzodiazepine Receptor Ligands, Memory and Information Processing (eds I. Hindmarch &H. Ott), pp. 218–229. Berlin: Springer-Verlag.Google Scholar
Gilleard, C. J., Morgan, K. & Wade, B. E. (1983) Patterns of neuroleptic use among the institutionalised elderly. Acta Psychiatrica of Scandinavica, 68, 419–425.Google Scholar
Goldhammer, Y., Bubis, J. J., Sarvona-Pinhas, I., et al (1972) Sub-acute spongioform emephalopathy and its relations to Jakob–Creutzfeld disease: report on six cases. Journal of Neurology, Neurosurgery and Psychiatry, 35, 1–10.Google Scholar
Goldstein, (1985) Dementia associated with alcoholism. Alcohol and the Brain: Chronic Effects (eds R. Tarter & D. M. Van Thiel). New York: Plenum.Google Scholar
Greenwald, B., Marin, D. & Silverman, S. M. (1986) Serotonergic treatment of screaming and banging in dementia. Lancet, ii, 1464–1465.CrossRefGoogle Scholar
Growden, J. H., Corkin, S., Huff, F. J., et al (1986) Piracetam combined with lecithin in the treatment of Alzheimer's disease. Neurobiology of Aging, 7, 269–276.Google Scholar
Gualtieri, B. (1988) Pharmacotherapy and the neurobehavioural sequelae of traumatic brain injury. Brain Injury, 2, 101–129.Google Scholar
Gurland, B. J., Teresi, J., McFate Smith, W., et al (1988) Effects of treatment for isolated systolic hypertension on cognitive status and depression in the elderly. Journal of the American Geriatric Society, 36, 1015–1022.CrossRefGoogle ScholarPubMed
Ter Haar, H. (1977) The relief of restlessnes in the elderly. Age and Aging, 6 (suppl.), 73–77.Google Scholar
Hamilton, L. D. & Bennett, J. L. (1962a) The use of trifluoperazine in geriatric patients with chronic organic brain syndrome. Journal of the American Geriatric Society, 10, 140–147.Google Scholar
Hamilton, L. D. & Bennett, J. L. (1962b) Acetophenazine for hyperactive geriatric patients. Geriatrics, 17, 596–601.Google Scholar
Hanley, I. G., McGuire, R. J. & Boyd, W. D. (1981) Reality orientation and dementia: a controlled trial of two approaches. British Journal of Psychiatry, 138, 10–14.Google Scholar
Harbaugh, R. E., Roberts, D. W., Coombs, D. W., et al (1984) Preliminary report: intracranial cholinergic drug infusion in patients with Alzheimer's disease. Neurosurgery, 15, 51.Google Scholar
Hardy, J., Adolfsso, R., Alafuzof, I., et al (1985) Transmitter deficits in Alzheimer's disease. Neurochemistry International, 7, 545–563.Google Scholar
Harper, C. (1983) The incidence of Wernicke's encephalopathy in Australia–neuropathological study of 131 cases. Journal of Neurology, Neurosurgery and Psychiatry, 46, 593–598.Google Scholar
Hefti, F. & Weiner, W. J. (1980) Nerve growth factor and Alzheimer's disease. Annals of Neurology, 20, 27–28.Google Scholar
Helms, P. M. (1985) Efficacy of antipsychotics in the treatment of the behavioral complications of dementia: a review of the literature. Journal of the American Geriatrics Society, 33, 206–209.CrossRefGoogle ScholarPubMed
Henderson, A. S. & Huppert, F. A. (1984) The problem of mild dementia. Psychological Medicine, 14, 5–11.Google Scholar
Herishanu, Y. (1973) Antiviral drugs in Jakob–Creutzfeld disease. Journal of the American Geriatrics Society, 21, 229–231.Google Scholar
Hollander, E., Mohs, R. C. & Davis, K. L. (1986) Cholinergic approaches to the treatment of Alzheimer's disease. British Medical Bulletin, 42, 97–100.CrossRefGoogle Scholar
Huppert, F. A. & Tym, E. (1986) Clinical and neuropsychological assessment of dementia. British Medical Bulletin, 42, 11–18.Google Scholar
Hyman, B. T., Eslinger, P. J. & Damasio, A. R. (1985) Effect of naltrexone on senile dementia of the Alzheimer type. Journal of Neurology, Neurosurgery and Psychiatry, 48, 1169–1171.Google Scholar
Jotkowitz, S. (1983) Physostigmine and A.D. Lack of clinical efficacy of chronic oral physostigmine in Alzheimer's disease. Annals of Neurology, 14, 690–691.Google Scholar
Jellinger, K. (1976) Neuropathological aspects of dementia resulting from abnormal blood and cerebrospinal fluid dynamics. Acta Neurologica Belgica, 76, 83–102.Google Scholar
Jellinger, K., Flament, H., Reiderer, P., et al (1980) Levodopa in the treatment of (pre) senile dementia. Mechanisms of Ageing and Development, 14, 253–264.Google Scholar
Jenike, M. (1986) Use of MAOIs for demented depressed patients. American Journal of Psychiatry, 143, 254.Google Scholar
Jenike, M., Albert, M. S., Heller, H., et al (1986) Combination therapy with lecithin and ergoloid mesylates for Alzheimer's disease. Journal of Clinical Psychiatry, 47, 249–251.Google ScholarPubMed
Kane, J. M. & Smith, J. M. (1982) Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Archives of General Psychiatry, 39, 473–481.Google Scholar
Karl, V. A. (1978) Benign, senescent forgetfulness in Alzheimer's disease. In Senile Dementia and Related Disorders (eds R. Katzman, R. D. Terry & K. L. Bick). New York: Raven Press.Google Scholar
Katzman, R. & Terry, R. D. (1983) The Neurology of Aging, pp. 1–14. Philadelphia: F. A. Davis & Co.Google Scholar
Kitigawa, Y., Meyer, J. S., Tachibana, H., et al (1984) CT–CBF correlations of cognitive deficits in multi-infarct dementia. Stroke, 15, 1000–1009.Google Scholar
Koob, G. F., Dantzer, R., Rodriguez, F., et al (1984) Osmotic stress mimics effects of vasopressin on learned behavior. Neuroscience Abstracts, 10, 169.Google Scholar
Koob, G. F., Lebrum, C., Martinez, J. L. Jr, et al (1985) Arginine vasopressin, stress and memory. Annals of New York Academy of Sciences, 444, 194–202.Google Scholar
Kopelman, M. D. & Lishman, W. A. (1986) Pharmacological treatments of dementia (non-cholinergic). British Medical Bulletin, 42, 101–105.Google Scholar
Kopelman, M. D. (1985) Multiple memory deficits in Alzheimer-type dementia: implications for pharmacotherapy. Psychological Medicine, 15, 527–541.Google Scholar
Kovanen, J., Haltia, M. & Cantell, K. (1980) Failure of interferon to modify Creutzfeldt–Jakob disease. British Medical Journal, 280, 902.Google Scholar
Kragh-Sorensen, P., Olsen, R. B., Lund, S., et al (1986) Neuropeptides: ACTH-peptides in dementia. Progress in Neuropharmacology, Biology and Psychiatry, 10, 479–492.Google Scholar
Kushnir, S. L. (1987) Pimozide in the management of psychotically agitated demented patients. Journal of the American Geriatrics Society, 35, 457–459.Google Scholar
La Boeuf, A., Lodge, J. L., Eames, P. G. (1978) Vasopressin and memory in Korsakov's syndrome. Lancet, ii, 23–30.Google Scholar
Legros, J. J., Gilot, P. E., Seron, X., et al (1978) Influence of vasopressin on learning and memory (letter). Lancet, i, 41–42.Google Scholar
Levy, R. (1978) Choline in Alzheimer's disease. Lancet, ii, 944–945.Google Scholar
Lichter, I., Richardson, P. & Wyke, M. (1986) Differential effects of atenolol and enalapril on memory during treatment for essential hypertension. British Journal of Clinical Pharmacology, 21, 641–645.Google Scholar
Lishman, W. A. (1986) Alcoholic dementia: a hypothesis. Lancet, i, 1184–1186.Google Scholar
Little, A., Levy, R., Chuaqui-Kidd, P., et al (1985) A double-blind placebo controlled trial of high dose lecithin in Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 48, 736–742.Google Scholar
Madden, D. S., Blumenthal, J. A., Ekelund, L. G., et al (1986) Memory performance by mild hypertensives following beta-adrenergic blockade. Psychopharmacology (Berlin), 89, 20–24.Google Scholar
Mair, R. G. & McEntee, W. J. (1983) Memory enhancement in Korsakoff's psychosis by clonidine: further evidence of a noradrenergic deficit. Behaviour Brain Research, 9, 1–32.Google Scholar
Mair, R. G. & McEntee, W. J. (1986) Cognitive enhancement in Korsakoff's psychosis by clonidine: a comparison with l-dopa and ephedrine. Psychopharmacology, 88, 374–380.Google Scholar
Mann, A. H., Jenkins, R., Cross, P. S., et al (1984) A comparison of the prescriptions received by the elderly in long-term care in New York and London. Psychological Medicine, 14, 891–897.Google Scholar
Manuelidis, E. E., Manuelidis, L., Pincus, J. H., et al (1978) Transmission from man to hamster of Creutzfelt–Jakob disease with clinical recovery. Lancet, ii, 40–42.Google Scholar
Marotta, R. F., Logan, N., Potegal, M., et al (1977) Dopamine agonists induce recovery from surgically-induced septal rage. Nature, 269, 513–515.Google Scholar
Marx, J. L. (1988) FDA queries Alzheimer's trial results. Science, 240, 969.Google Scholar
Martin, P. K., Ebert, M. H., Gordon, E. K., et al (1983) Urinary catecholamine metabolites and effects of clonidine in patients with alcohol amnesic disorder. Clinical Pharmacology and Therapeutics, 33, 19–27.Google Scholar
May, W. W. (1968) Creutzfeldt–Jakob disease. Survey of the literature and clinical diagnosis. Acta Neurologica Scandinavica, 44, 1–32.Google Scholar
McDevitt, D. G. (1985) Beta-blockers and psychometric performance: studies in normal volunteers. European Journal of Clinical Pharmacology, 28 (suppl.), 35–38.Google Scholar
McEntee, W. J. & Mair, R. G. (1978) Memory impairment in Korsakoff's psychosis: a correlation with brain nor-adrenergic activity. Science, 202, 905–907.Google Scholar
McEntee, W. J. & Mair, R. G. (1980) Memory enhancement in Korsakoff's psychosis by clonidine: further evidence for a noradrenergic deficit. Annals of Neurology, 7, 466–470.Google Scholar
McEntee, W. J., Mair, R. G. & Langlais, P. J. (1984) Neurochemical specificity of learning: dopamine and motor learning. Yale Journal of Biological Medicine, 60, 187–193.Google Scholar
Medical Research Council Working Party (1985) MRC trial of treatment of mild hypertension: principal results. British Medical Journal, 291, 97–104.Google Scholar
Meyer, J. S., Judd, B. W., Tawakina, T., et al (1986) Improved cognition after control of risk factors for multi-infarct dementia. Journal of the American Medical Association, 256, 2203–2209.Google Scholar
Meyer, J. S., Rogers, R. L., Judd, B. W., et al (1988a) Cognition and cerebral blood flow fluctuate together in multi-infarct dementia. Stroke, 19, 163–169.Google Scholar
Meyer, J. S., McClintic, K. L., Rogers, R. L., et al (1988b) Aetiological considerations and risk factors for multi-infarct dementia. Journal of Neurology, Neurosurgery and Psychiatry, 51, 489–497.Google Scholar
Michel, K. & Kolakowska, T. (1981) A survey of prescribing psychotropic drugs in two psychiatric hospitals. British Journal of Psychiatry, 138, 217–221.Google Scholar
Miller, E. (1981) The nature of the cognitive deficit in senile dementia. In Clinical Aspects of Alzheimer's Disease and Senile Dementia. Aging. 15. (eds N. E. Miller, G. D. Cohen). New York: Raven Press.Google Scholar
Mohr, E., Schlegel, J., Fabbrini, G., et al (1989) Clonidine treatment of Alzheimer's disease. Archives of Neurology, 48, 376–378.CrossRefGoogle Scholar
Mohs, R. C., Davis, B. M., Johns, C. A., et al (1985a) Oral physostigmine treatment of patients with Alzheimer's disease. American Journal of Psychiatry, 142, 28–33.Google Scholar
Mohs, R. C., Davis, B. M., Greenwald, B. S., et al (1985b) Clinical studies of the cholinergic deficit in Alzheimer's disease: II. Psychopharmacologic studies. Journal of the American Geriatric Society, 33, 749–757.Google Scholar
Morgan, K., Gilleard, C. J. & Reive, A. (1982) Hypnotic usage in residential homes for the elderly: a prevalence and longitudinal analysis. Age and Ageing, II, 229–234.Google Scholar
Muramato, O., Sugashita, M. (1979) Effect of physostigmine on constructional and memory tasks in Alzheimer's disease. Archives of Neurology, 36, 501–503.Google Scholar
Newman, P. K. (1984) Acyclovir in Creutzfeldt–Jakob disease. Lancet, i, 793.Google Scholar
Oliveros, J. C., Jandali, M. K., Timsit-Berthier, M., et al (1978) Vasopressin in amnesia (letter). Lancet, i, 42.Google Scholar
O'Neil, M., Page, N., Adkins, W., et al (1986) Tryptophan-trazodone treatment of aggressive behaviour. Lancet, ii, 859–60.Google Scholar
Partanen, J. V., Soininen, H. & Riekkinen, P. J. (1986) Does an ACTH derivative (Org 2766) prevent deterioration of EEG in Alzheimer's disease? Electroencephalography and Clinical Neurophysiology, 63, 547–551.Google Scholar
Pathy, M. S., Bayer, A. J. & Stoker, M. J. (1986) A double-blind comparison of chlormethiazole and temazepam on elderly patients with sleep disturbances. Acta Psychiatrica Scandinavica, 329, 99–103.Google Scholar
Paulson, G. W. (1983) Steroid-sensitive dementia. American Journal of Psychiatry, 140, 1031–1033.Google Scholar
Peabody, C. A., Thiemann, S., Pigache, R., et al (1985) Desglycinamide–9-arginine–8-vasopressin (DGAVP, Organon 5667) in patients with dementia. Neurobiology of Aging, 6, 95–100.Google Scholar
Peabody, C. A., Deblois, T. E. & Tinklenberg, J. B. (1986a) Thyrotropin-releasing hormone (TRH) and Alzheimer's disease. American Journal of Psychiatry, 143, 262–263.Google Scholar
Peabody, C. A., Davies, H., Berger, P. A., et al (1986b) Desamino-d-arginine-vasopressin (DDAVP) on Alzheimer's disease. Neurobiology of Aging, 7, 301–303.Google Scholar
Perry, E. K. (1988) Acetylcholine and Alzheimer's disease. British Journal of Psychiatry, 152, 737–740.Google Scholar
Perry, E. K., Tomlinson, B. E. & Blessed, G. (1978) Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. British Medical Journal, ii, 1457–1459.Google Scholar
Perry, E. K., Curtis, M., Dick, D. J., et al (1985) Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 48, 413–421.CrossRefGoogle ScholarPubMed
Peters, B. M. & Levin, H. S. (1979) Physostigmine and lecithin on memory in Alzheimer's disease. Annals of Neurology, 6, 219–221.Google Scholar
Petrie, W. M. & Ban, T. A. (1981) Propranolol in organic agitation (letter). Lancet, i, 324.Google Scholar
Petrie, W. M., Ban, T. A., Berney, S., et al (1982) Loxapine in psychogeriatrics: a placebo and standard controlled clinical investigation. Journal of Clinical Psychopharmacology, 2, 122–126.Google Scholar
Pigache, R. M. (1983) The human psychopharmacology of peptides related to ACTH and alpha MSH. In Clinical Pharmacology in Psychiatry (eds L. Gram et al). London: Macmillan.Google Scholar
Pigache, R. M. & Rioter, H. (1981) Effects of peptides related to ACTH on mood and vigilance in man. Frontiers of Hormone Research, 8, 193–207.Google Scholar
Pirozzolo, F. J., Baskin, D. S., Swihart, A. A. et al (1987) Oral tetrahydramintacridine in the treatment of senile dementia, Alzheimer's type. New England Journal of Medicine, 316, 1605.Google Scholar
Pomara, N., Banay-Schwartz, M., Block, R., et al (1985) Multiple single dose naltrexone administrations fail to affect overall cognitive functioning and plasma Cortisol in individuals with probable Alzheimer's disease. Neurobiology of Ageing, 6, 233–236.Google Scholar
Quarton, G. C., Clark, L. K., Cobb, S., et al (1955) Mental disturbance associated with ACTH and cortisone: a review of explanatory hypotheses. Medicine, 34, 13–50.Google Scholar
Rada, R. T. & Kellner, R. (1976) Thiothixene in the treatment of geriatric patients with chronic organic brain syndrome. Journal of the American Geriatrics Society, 24, 105–107.Google Scholar
Rajagopalan, B., Raine, A. E. G., Cooper, R., et al (1984) Changes in the cerebral blood flow in patients with severe congestive heart failure before and after captopril treatment. American Journal of Medicine, 76 (suppl. 58), 86–90.Google Scholar
Raskind, M. A., Risse, S. C. & Lampe, T. H. (1987) Dementia and antipsychotic drugs. Journal of Clinical Psychiatry, 48, 16–18.Google Scholar
Reisberg, B., Ferris, S. H., Anand, R., et al (1983) Effects of naloxone in senile dementia: a double-blind trial. New England Journal of Medicine, 308, 721–722.Google Scholar
Reisberg, B., Borstein, J., Salob, S. P., et al (1987) Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. Journal of Clinical Psychiatry, 48, 9–15.Google Scholar
Risse, S. C. & Barnes, R. (1986) Pharmacological treatment of agitation associated with dementia. Journal of the American Geriatric Society, 34, 368–376.Google Scholar
Robbins, T. W. (1988) Alzheimer's disease: Arresting a memory decline. Nature, 336, 207–208.Google Scholar
Rogers, R. L., Meyer, J. S., Mortel, K. F., et al (1986) Decreased cerebral blood flow precedes multi-infarct dementia, but follows senile dementia of Alzheimer type. Neurology, 36, 1–6.Google Scholar
Rosen, W. G., Mohs, R. C. & Davis, K. L. (1984) A new rating scale for Alzheimer's disease. American Journal of Psychiatry, 141, 1356–1364.Google Scholar
Rosenberg, M. B., Breakefield, X. O. & Hawrot, E. (1987) Targeting of liposomes to cells bearing NGF receptors mediated by biotinylated NGF. Journal of Neurochemistry, 47, 865–875.Google Scholar
Rubin, E. H., Morris, J. C., Grant, E. A., et al (1989) Very mild dementia of the Alzheimer type. Archives of Neurology, 46, 379–382.Google Scholar
Sable, H. Z. & Guber, C. J. (1982) Thiamin: twenty years of progress. Annals of New York Academy and Science, 378.Google Scholar
Sanders, W. L. (1979) Creutzfeldt–Jakob disease treated with amantidine. Journal of Neurology, Neurosurgery and Psychiatry, 42, 960–961.Google Scholar
Sanders, W. L. & Dunn, T. L. (1973) Creutzfeldt–Jakob disease treated with amantidine. A report of two cases. Journal of Neurology, Neurosurgery and Psychiatry, 42, 960–961.Google Scholar
Sarter, M., Schneider, N., & Stephens, D. N. (1988) Treatment strategies for senile dementia: antagonist beta carbolines. Trends in Neurosciences, 11, 13.Google Scholar
Scheinberg, P. (1988) Dementia due to vascular disease–a multifactorial disorder. Stroke, 19, 1291–1299.Google Scholar
Schreier, H. A. (1979) Use of propranolol in the treatment of postencephalitic psychosis. American Journal of Psychiatry, 136, 840–841.Google Scholar
Schwarcz, R., Whetsell, W. O. & Mangano, R. M. (1982) Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science, 219, 316–318.Google Scholar
Schwarcz, R. & Meldrum, B. (1985) Excitatory aminoacid antagonists provide a therapeutic approach to neurological disorders. Lancet, ii, 140–143.Google Scholar
Seager, C. P. (1955) Chlorpromazine in the treatment of elderly psychotic women. British Medical Journal, i, 882–885.Google Scholar
Serby, M., Resnick, R., Jordan, B., et al (1986) Naltrexone and Alzheimer's disease. Progress in Neuropsychopharmacology, Biology and Psychiatry, 10, 587–590.Google Scholar
Sims, N. R., Bowen, D. M., Smith, C. C. T., et al (1980) Glucose metabolism and acetylcholine synthesis in relation to neuronal activity in Alzheimer's disease. Lancet, i, 333–335.Google Scholar
Smith, C. M. & Swash, M. (1979) Physostigmine in Alzheimer's disease (letter). Lancet, i, 42.Google Scholar
Solomons, S., Hotchkiss, E., Saravay, S., et al (1985) Impairment of memory function by antihypertensive medication. Archives of General Psychiatry, 40, 1109–1112.Google Scholar
Steiger, W. A., Mendelson, M., Jenkins, T., et al (1985) Effects of naloxone in treatment of senile dementia (letter). Journal of the American Geriatric Society, 33, 155.Google Scholar
Steele, C. L., Lucas, M. J. & Tune, L. (1986) Haloperidol versus thioridazine in the treatment of behavioral symptoms in senile dementia of the Alzheimer's type: preliminary findings. Journal of Clinical Psychiatry, 47, 310–312.Google Scholar
Strandgaard, S. (1976) Autoregulation of cerebral blood flow in hypertensive patients. The modifying influence of a prolonged antihypertensive treatment on the tolerance to acute, drug-induced hypertension. Circulation, 53, 720–727.Google Scholar
Strandgaard, S., Olesen, J., Skinhje, E., et al (1973) Autoregulation of brain circulation in severe arterial hypertension. British Medical Journal, i, 507–510.CrossRefGoogle ScholarPubMed
Sugerman, A. A., Williams, B. H. & Alderstein, A. M. (1964) Haloperidol in the psychiatric disorders of old age. American Journal of Psychiatry, 120, 1190–1192.Google Scholar
Summers, W. K., Majovski, L. V., Marsh, G. M., et al (1986) Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer's type. New England Journal of Medicine, 315, 1241–1245.Google Scholar
Sunderland, T. & Silver, M. A. (1988) Neuroleptics in the treatment of dementia. International Journal of Geriatric Psychiatry, 3, 79–88.Google Scholar
Tamminga, C. A., Durso, R., Feido, P., et al (1982) Vasopressin studies in Alzheimer's disease. Psychopharmacological Bulletin, 18, 48–49.Google Scholar
Tariot, P. N., Sunderland, T., Weingartner, H., et al (1985) Low and high-dose naloxone in dementia of the Alzheimer type. Psychopharmacology Bulletin, 21, 680–682.Google Scholar
Tariot, P. N., Cohen, R. M., Sunderland, T., et al (1987) L-deprenyl in Alzheimer's disease. Preliminary evidence for behavioural change with monoamine oxidase B inhibition. Archives of General Psychiatry, 44, 427–433.Google Scholar
Tariot, P. N. & Caine, E. D. (1987) Oral tetrahydroaminoacridine in the treatment of senile dementia. Alzheimer's type (letter). New England Journal of Medicine, 316, 1605.Google Scholar
Tariot, P. N., Caine, E. D., Welkovitz, J. A., et al (1988) Multiple-dose arecoline infusions in Alzheimer's disease. Archives of General Psychiatry, 45, 901–905.Google Scholar
Tariot, P. N., Sunderland, T., Weingartner, H., et al (1986) Naloxone and Alzheimer's disease. Archives of General Psychiatry, 43, 727–732.Google Scholar
Tarter, R. & Alterman, A. (1984) Neuropsychological deficits in chronic alcoholics: etiological considerations. Journal of Studies on Alcohol, 45, 1–9.Google Scholar
Terzano, M. J., Montonari, E., Calzetti, S., et al (1983) The effect of amantadine on arousal and EEG patterns in Creutzfeldt-Jakob disease. Archives of Neurology, 40, 555–559.Google Scholar
Thal, L. J., Fuld, P. A. & Masur, D. M. (1983) Oral physostigmine and lecithin improve memory in Alzheimer's disease. Annals of Neurology, 13, 491–496.Google Scholar
Thal, L. J., Masur, D. M., Blau, A. D., et al (1989) Chronic oral physostigmine without lecithin improves memory in Alzheimer's disease. Journal of the American Geriatrics Society, 37, 42–48.Google Scholar
Ulus, I. & Wurtman, R. (1976) Choline administration: activation of tyrosine hydroxylase in dopaminergic neurons of rat brain. Science, 194, 1060–1061.Google Scholar
Victor, M., Adams, R. D. & Collins, G. H. (1971) The Wernicke -Korsakoff syndrome. A clinical and pathological study of 245 patients, 82 with post-mortem examinations. Contemporary Neurology Series 7. Philadelphia: F. A. Davis.Google Scholar
Ward, A. A. & Kennard, M. A. (1942) Effect of cholinergic drugs on recovery of function following lesions of the nervous system in monkeys. Yale Journal of Biology and Medicine, 15, 189–228.Google Scholar
de Weid, D. (1969) Effects of peptide hormones on behavior. Frontiers in Neuroendocrinology, 97–140.Google Scholar
de Weid, D. (1976) Hormonal influences on motivation learning and memory processes. Hospital Practice, January, 11, 123–131.Google Scholar
Weingartner, H., Kaye, W., Gold, P., et al (1981a) Effect of vasopressin on human memory function. Science, 211, 601–603.Google Scholar
Weingartner, H., Kaye, W., Gold, P., et al (1981b) Vasopressin treatment of cognitive dysfunction in progressive dementia. Life Sciences, 29, 2721–2726.Google Scholar
Weiss, B. L. (1987) Failure of nalmefene and estrogen to improve memory in Alzheimer's disease. American Journal of Psychiatry, 144, 386–387.Google Scholar
Welstein, A. (1983) No effect from a double blind trial of physostigmine and lecithin in Alzheimer's disease. Annals of Neurology, 13, 210–217.Google Scholar
Williams, D., Menl, R., Yudofsky, S., et al (1982) The effect of propranolol on uncontrolled rage outbursts in children and adolescents with organic brain dysfunction. Journal American Academy of Child Psychiatry, 21, 129–135.Google Scholar
Yarbrouoh, G. G. (1979) On the neuropharmacology of thyrotrophin releasing hormone (TRH). Progress in Neurobiology, 12, 291–312.Google Scholar
Yarbrouoh, G. G. & Pomara, N. (1985). The therapeutic potential of thyrotrophin releasing hormone (TRH) in Alzheimer's disease (AD). Progress in Neuropsychopharmacology and Biological Psychiatry, 9, 285–289.CrossRefGoogle Scholar
Yufodfsky, S., Williams, D. & Gorman, J. (1981) Propranolol in the treatment of patients with chronic brain syndrome. American Journal of Psychiatry, 138, 218–220.Google Scholar
Zemektin, A., Rapoport, J. L. & Murphy, D. L. (1985) Treatment of hyperactive children with monoamine oxidase inhibitors. Archives of General Psychiatry, 42, 962–976.Google Scholar
Zivin, J. A., Fisher, M., Degirolami, U., et al (1985) Tissue plasminogen activator reduces neurological damage after cerebral embolism. Science, 230, 1289–1292.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.